Abstract
Oropouche fever is a neglected tropical viral disease endemic to Latin America and the Caribbean. Oropouche fever is caused by Oropouche virus (OROV), an orthobunyavirus with a tri-segmented (-)ssRNA genome. A recent epidemic caused by a novel reassortant has seen the first recorded deaths from OROV infection and reports of vertical transmission, affecting individuals across a dramatically expanded geographical range. Despite its importance as an emerging pathogen, research into OROV infection is hampered by paucity of available tools for serology and molecular virology. We have purified high-quality recombinant OROV nucleoprotein and the spike region of the viral surface glycoprotein Gc. We have used these antigens in indirect ELISA to detect seroconversion following experimental infection of animals, confirming their antigenic authenticity. These antigens stimulate the production of high neutralizing antibody titres in animals, highlighting their promise as immunogens for vaccination. We generated nanobodies that recognize both recombinant and infection-derived OROV antigens and developed a sandwich ELISA assay that can detect OROV antigens in human clinical serum samples with high efficiency. We have also shown that recombinant nanobodies directed against OROV Gc spike can potently neutralise infection by both historical OROV strains and the newly emerged reassortant. These protein-based reagents will accelerate OROV research and highlight the utility of protein-based tools for future OROV vaccines and point-of-care diagnostic devices.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by a Biotechnology and Biological Sciences Research Council (BBSRC) grant to RJO (BB_V018523), an International Collaboration Award from the Royal Society to EA and SCG (ICA\R1\201019), a Sao Paulo Research Foundation (FAPESP) grant to EA (19/26119-0), and International Science Partnerships Fund (ISPF) Institutional Support Grant (ODA) from Research England to SCG. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Fundacao de Medicina Tropical Dr. Heitor Vieira Dourado gave ethical approval under registration number 700.915.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Conceptualisation: EA, SCG; Data Curation: SCG; Funding Acquisition: RJO, EA, SCG; Investigation: MKM, JdPS, SA, SC, TANN, KIGM, DMdMJ, VAdN, YS, ERC, LEAE, JSR, ICRP, SDP, MHPdS, FRdN, SCG; Project Administration: RJO, EA, SCG; Resources: FGN, JLPM, RPMdF; Supervision: LLPdS, RJO, EA, SCG; Visualisation: MKM, JdPS, SCG; Writing – Original Draft Preparation: SCG; Writing – Review & Editing: MKM, JdPS, KIGM, DMdMJ, JSR, JLPM, LLPdS, RMPdF, RJO, EA, SCG
Data availability
The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials. Plasmids encoding the proteins described in this study, and selected cell lines plus purified proteins, will be made available from the Centre for Infectious Disease Reagents (https://nibsc.org/science_and_research/idd/cfar.aspx), UK Medicines and Healthcare products Regulatory Agency, upon publication.
